The PPD clinical research arm of Thermo Fisher Scientific has consistently been acknowledged as an industry leader in digital solutions and services for four consecutive years by Information Services Group (ISG).
ISG’s recognition highlights PPD’s expertise in digital transformation services for clinical development, patient engagement, pharmacovigilance, and regulatory affairs. The business has been praised for enhancing patient access to clinical trials for promising therapies.
PPD excels in decentralized trials, offering expertise in diverse therapeutic areas and customized solutions for patient engagement. The business emphasizes overcoming barriers like lack of awareness, accessibility, and socioeconomic challenges.
PPD’s advanced disease simulation, modeling, comprehensive pharmacovigilance, and regulatory solutions featuring artificial intelligence integration have also earned recognition. The business leverages technology to streamline processes like case processing, safety profiling, and regulatory intelligence.
Brittany Erana, Vice President and General Manager of Patient First Digital Solutions at Thermo Fisher Scientific indicated that they are honored by ISG’s recognition, which underscores their unwavering leadership, and that they prioritize patient-centered research and embrace technology to improve the patient experience.
Thermo Fisher Scientific’s commitment to R&D, with a $1.3 billion investment in 2023, supports the development of innovative technologies, including those employed by PPD.
ISG’s Provider Lens Quadrant, based on an independent review of life science companies offering digital services, places PPD among the top 20 companies for industry-specific capabilities.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
